应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
CMPS COMPASS Pathways plc
休市中 09-11 16:00:00 EDT
14.35
+0.13
+0.91%
盘后
14.39
+0.04
+0.28%
19:49 EDT
最高
14.65
最低
14.13
成交量
201.56万
今开
14.13
昨收
14.22
日振幅
3.66%
总市值
19.80亿
流通市值
15.35亿
总股本
1.38亿
成交额
2,898万
换手率
1.88%
流通股本
1.07亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Compass Pathways公布美国资助计划入选者,旨在推进Comp360获批后供应商培训项目
美股速递 · 09-10 18:36
Compass Pathways公布美国资助计划入选者,旨在推进Comp360获批后供应商培训项目
Compass Pathways 25毫克组在第52周实现MADRS平均降低13点,疗效持续至一年
美股速递 · 09-09
Compass Pathways 25毫克组在第52周实现MADRS平均降低13点,疗效持续至一年
Compass Pathways:Comp360在C部分的安防特性与此前阶段保持一致,无新增安全性发现
美股速递 · 09-09
Compass Pathways:Comp360在C部分的安防特性与此前阶段保持一致,无新增安全性发现
Compass Pathways发布COMP005三期试验52周开放标签顶线数据:Part C部分追加COMP360剂量,疗效持久性延长至一年
美股速递 · 09-09
Compass Pathways发布COMP005三期试验52周开放标签顶线数据:Part C部分追加COMP360剂量,疗效持久性延长至一年
Compass Pathways携手美国退伍军人事务部,推进裸盖菇素临床研究
美股速递 · 08-06
Compass Pathways携手美国退伍军人事务部,推进裸盖菇素临床研究
错峰抄底重仓特斯拉 木头姐ARK Invest完成全品类持仓调仓
金吾财讯 · 07-27
错峰抄底重仓特斯拉 木头姐ARK Invest完成全品类持仓调仓
COMPASS Pathways股价盘前大涨8.6%,抑郁症疗法后期试验数据积极
美股速递 · 07-07
COMPASS Pathways股价盘前大涨8.6%,抑郁症疗法后期试验数据积极
COMPASS Pathways公布第二阶段三期试验六个月数据,证实快速且持久的疗效特征
美股速递 · 07-07
COMPASS Pathways公布第二阶段三期试验六个月数据,证实快速且持久的疗效特征
COMPASS Pathways旗下COMP360持续展现良好耐受性与安全性,未发现新安全风险
美股速递 · 07-07
COMPASS Pathways旗下COMP360持续展现良好耐受性与安全性,未发现新安全风险
COMPASS Pathways宣布FDA批准新药申请滚动审评请求并授予专员国家优先审评券
美股速递 · 04-24
COMPASS Pathways宣布FDA批准新药申请滚动审评请求并授予专员国家优先审评券
特朗普签署行政令加速PTSD疗法研发:美迷幻药物板块迎来“结构性拐点”,盘前全线飙升!
智通财经 · 04-20
特朗普签署行政令加速PTSD疗法研发:美迷幻药物板块迎来“结构性拐点”,盘前全线飙升!
COMPASS Pathways公司已就抗抑郁疗法Comp360向FDA启动滚动申报程序
美股速递 · 04-19
COMPASS Pathways公司已就抗抑郁疗法Comp360向FDA启动滚动申报程序
COMPASS Pathways推出美国资助计划,旨在建立批准后Comp360服务提供商培训体系
美股速递 · 04-14
COMPASS Pathways推出美国资助计划,旨在建立批准后Comp360服务提供商培训体系
COMPASS Pathways公司:截至2024年3月现金状况预计足以支撑运营支出及资本支出至2028年
美股速递 · 03-24
COMPASS Pathways公司:截至2024年3月现金状况预计足以支撑运营支出及资本支出至2028年
Compass Pathways Plc盘中异动 股价大跌5.04%
市场透视 · 2025-03-10
Compass Pathways Plc盘中异动 股价大跌5.04%
Compass Pathways Plc2024财年实现净利润-1.55亿美元,同比减少30.25%
市场透视 · 2025-03-07
Compass Pathways Plc2024财年实现净利润-1.55亿美元,同比减少30.25%
Compass Pathways Plc盘中异动 快速拉升5.06%报4.05美元
市场透视 · 2025-03-06
Compass Pathways Plc盘中异动 快速拉升5.06%报4.05美元
Compass Pathways Plc盘中异动 下午盘急速上涨5.09%
市场透视 · 2025-03-05
Compass Pathways Plc盘中异动 下午盘急速上涨5.09%
Compass Pathways Plc盘中异动 股价大跌5.22%
市场透视 · 2025-03-04
Compass Pathways Plc盘中异动 股价大跌5.22%
Compass Pathways Plc盘中异动 早盘股价大跌5.10%
市场透视 · 2025-02-28
Compass Pathways Plc盘中异动 早盘股价大跌5.10%
加载更多
公司概况
公司名称:
COMPASS Pathways plc
所属市场:
NASDAQ
上市日期:
--
主营业务:
COMPASS Pathways plc最初于2020年6月根据英格兰和威尔士法律成立为一家私人有限公司。该公司是一家生物技术公司,致力于加速推动患者获得基于证据的精神健康创新疗法。该公司正在通过开发他们的研究性COMP360 psilocybin治疗,开创一种以快速和持久反应为重点的治疗心理健康状况的新范式,这可能是同类治疗中的首创。COMP360是他们专有的裸盖菇素制剂,其中包括他们的医药级多形结晶裸盖菇素,针对稳定性和纯度进行了优化。
发行价格:
--
{"stockData":{"symbol":"CMPS","market":"US","secType":"STK","nameCN":"COMPASS Pathways plc","latestPrice":14.35,"timestamp":1789156800000,"preClose":14.22,"halted":0,"volume":2015599,"hourTrading":{"tag":"盘后","latestPrice":14.39,"preClose":14.35,"latestTime":"19:49 EDT","volume":74494,"amount":1069022.6984,"timestamp":1789170557782,"change":0.04,"changeRate":0.002787,"amplitude":0.022732},"delay":0,"changeRate":0.009142053445850843,"floatShares":107000000,"shares":138000000,"eps":-3.611848,"marketStatus":"休市中","change":0.13,"latestTime":"09-11 16:00:00 EDT","open":14.13,"high":14.65,"low":14.13,"amount":28976896.21568,"amplitude":0.036568,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.611848,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":14.22,"preHourTrading":{"tag":"盘前","latestPrice":14.37,"preClose":14.22,"latestTime":"09:29 EDT","volume":16693,"amount":239547.82182800001,"timestamp":1789133349787,"change":0.15,"changeRate":0.010549,"amplitude":0.041491},"postHourTrading":{"tag":"盘后","latestPrice":14.39,"preClose":14.35,"latestTime":"19:49 EDT","volume":74494,"amount":1069022.6984,"timestamp":1789170557782,"change":0.04,"changeRate":0.002787,"amplitude":0.022732},"volumeRatio":0.59090287045878,"impliedVol":0.6167,"impliedVolPercentile":0.0199},"requestUrl":"/m/hq/s/CMPS","defaultTab":"news","newsList":[{"id":"1100081863","title":"Compass Pathways公布美国资助计划入选者,旨在推进Comp360获批后供应商培训项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1100081863","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100081863?lang=zh_cn&edition=full","pubTime":"2026-09-10 18:36","pubTimestamp":1789036568,"startTime":"0","endTime":"0","summary":"Compass Pathways正式揭晓了美国资助计划的获选名单。这项计划聚焦于Comp360产品在获得监管批准之后的供应商培训事宜。通过这一举措,公司希望为相关培训体系的搭建提供有力支持。入选的机构将在后续阶段发挥关键作用,协助推动培训内容的开发与实施。此次公布的名单标志着该计划进入实质性推进阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168737220","title":"Compass Pathways 25毫克组在第52周实现MADRS平均降低13点,疗效持续至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1168737220","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1168737220?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:36","pubTimestamp":1788950183,"startTime":"0","endTime":"0","summary":"Compass Pathways的25毫克剂量组在第52周呈现出平均13分的MADRS评分降幅,且这一改善效果能够稳定维持长达一年之久。这一结果不仅彰显了治疗方案的持续有效性,也为其在长期临床应用中提供了有力佐证。疗效的持久性无疑成为该研究中最引人瞩目的亮点之一。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161980382","title":"Compass Pathways:Comp360在C部分的安防特性与此前阶段保持一致,无新增安全性发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1161980382","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161980382?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:33","pubTimestamp":1788950025,"startTime":"0","endTime":"0","summary":"Compass Pathways宣布,其核心候选药物Comp360在临床试验C部分的安防特性与此前的试验阶段呈现一致性,未观察到新的安全性问题。这一发现为药物的后续研发推进提供了积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195512633","title":"Compass Pathways发布COMP005三期试验52周开放标签顶线数据:Part C部分追加COMP360剂量,疗效持久性延长至一年","url":"https://stock-news.laohu8.com/highlight/detail?id=1195512633","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195512633?lang=zh_cn&edition=full","pubTime":"2026-09-09 18:31","pubTimestamp":1788949897,"startTime":"0","endTime":"0","summary":"COMPASS Pathways公司近日公布了其三期临床试验COMP005的52周开放标签顶线数据。结果显示,在Part C阶段,受试者接受额外一剂COMP360治疗后,疗效持续时间得以显著延伸——长达整整一年之久。COMPASS Pathways 此前已多次强调,COMP360 的长期疗效管理是其临床开发战略的核心关注点之一。业内分析人士指出,尽管开放标签数据在证据等级上不及随机对照试验,但长期随访数据对于注册审评及临床实践指导同样不可或缺。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151539682","title":"Compass Pathways携手美国退伍军人事务部,推进裸盖菇素临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1151539682","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1151539682?lang=zh_cn&edition=full","pubTime":"2026-08-06 18:43","pubTimestamp":1786012989,"startTime":"0","endTime":"0","summary":"Compass Pathways正与美国退伍军人事务部展开合作,旨在共同推进一项针对裸盖菇素的临床研究。这项实验性研究标志着在精神健康治疗领域迈出了新的一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654010113","title":"错峰抄底重仓特斯拉 木头姐ARK Invest完成全品类持仓调仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2654010113","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654010113?lang=zh_cn&edition=full","pubTime":"2026-07-27 20:12","pubTimestamp":1785154356,"startTime":"0","endTime":"0","summary":"金吾财讯|凯茜·伍德旗下ARK Invest完成大规模双向调仓操作,整体延续聚焦AI、自动驾驶、太空科技、创新医疗、金融科技的核心投资主线,在多赛道加码优质标的,同时对部分科技、工业、医疗标的获利减持,持仓结构进一步优化。本期最大手笔增持为特斯拉,在特斯拉二季度财报不及预期、单日暴跌约15%创下一年最大单日跌幅后,ARK Invest逆势加仓价值5270万美元的特斯拉股票。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/NjJmZjg2MTAxNTM3NTgyMzkx.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"303054","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SARK","ACHR","OGIG","ROKU","IRDM","ARKW","ARKG","CDNA","BULZ","IXJ","BIDU","ILMN","SRTA","SMH","SNOW","AMD","CAT","ARKF","CRCL","ARKB","CMPS","LTL","ARKQ","PRME","ESLT","LLY","VEGI","ABSI","META","SCTX","SHOP","YMAG","NTRA","FIG","ARKK","TSLL","TWST","SHPD","MAGY","ARKX","XE","TER","DE","AMDL","TXG","HOOD","ATAI","TEM","TSLA"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1139021636","title":"COMPASS Pathways股价盘前大涨8.6%,抑郁症疗法后期试验数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=1139021636","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139021636?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:42","pubTimestamp":1783420930,"startTime":"0","endTime":"0","summary":"在公布其抑郁症治疗药物的积极后期试验数据后,COMPASS Pathways plc的股价在盘前交易时段飙升了8.6%。这一显著涨幅反映了市场对该药物研发进展的乐观情绪,以及其未来商业潜力的认可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104642085","title":"COMPASS Pathways公布第二阶段三期试验六个月数据,证实快速且持久的疗效特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1104642085","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104642085?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:33","pubTimestamp":1783420411,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc宣布,其第二阶段三期临床试验的六个月数据已公布,结果证实了其疗法具备快速起效且疗效持久的特征。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175403731","title":"COMPASS Pathways旗下COMP360持续展现良好耐受性与安全性,未发现新安全风险","url":"https://stock-news.laohu8.com/highlight/detail?id=1175403731","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175403731?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:32","pubTimestamp":1783420321,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc 公布的数据表明,其研究性疗法COMP360继续展现出良好的耐受性与安全性特征,且未出现新的安全性发现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102269560","title":"COMPASS Pathways宣布FDA批准新药申请滚动审评请求并授予专员国家优先审评券","url":"https://stock-news.laohu8.com/highlight/detail?id=1102269560","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102269560?lang=zh_cn&edition=full","pubTime":"2026-04-24 22:38","pubTimestamp":1777041494,"startTime":"0","endTime":"0","summary":"生物医药公司COMPASS Pathways plc宣布,美国食品药品监督管理局(FDA)已正式批准其新药申请(NDA)的滚动审评请求,同时授予专员国家优先审评券。这一重要进展将显著加速该公司创新疗法的审评进程。\n滚动审评机制允许制药企业分阶段提交NDA资料,而非一次性提交完整申请材料,有助于FDA更早介入审评流程。国家优先审评券的授予进一步体现了该疗法在解决未满足医疗需求方面的重要价值,将为后续审评提供优先通道。\n此次监管突破标志着COMPASS Pathways在精神健康领域创新药物研发取得实质性进展,为公司核心产品的商业化奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628742200","title":"特朗普签署行政令加速PTSD疗法研发:美迷幻药物板块迎来“结构性拐点”,盘前全线飙升!","url":"https://stock-news.laohu8.com/highlight/detail?id=2628742200","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2628742200?lang=zh_cn&edition=full","pubTime":"2026-04-20 19:23","pubTimestamp":1776684215,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,在美国总统特朗普签署了一项旨在加速研究并扩大对用于治疗创伤后应激障碍的海外物质的获取渠道的行政令后,迷幻药物相关股票在盘前交易中上涨。投行奥本海默分析师杰伊·奥尔森表示,特朗普的行政令“通过促进研究、简化监管时间表和扩大患者获取渠道,代表了美国迷幻药物行业的一个结构性拐点,这强化了我们的积极展望”。报告指出,这是该领域取得的又一积极进展,利好 RBC 覆盖的迷幻药物公司:Definium Therapeutics、Compass Pathways 和 GH Research。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430797.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0128525929.USD","LU1267930573.SGD","BK4007","BK4139","CMPS","BK4539","IE00BLDYK493.USD","BK4127","BK4009","BK4161","LU0310800379.SGD","BK4207","GHRS","ATAI","BK4559","LU0029864427.USD","LU0708994859.HKD","LU2065731478.USD","HELP","IE00B64QTZ34.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1114958406","title":"COMPASS Pathways公司已就抗抑郁疗法Comp360向FDA启动滚动申报程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1114958406","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1114958406?lang=zh_cn&edition=full","pubTime":"2026-04-19 04:17","pubTimestamp":1776543432,"startTime":"0","endTime":"0","summary":"COMPASS Pathways公司宣布,针对其创新疗法Comp360在治疗耐药性抑郁症领域的应用,已与美国食品药品监督管理局(FDA)展开滚动申报程序的合作。这一进展标志着该公司在精神健康治疗领域的研发迈出关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130056728","title":"COMPASS Pathways推出美国资助计划,旨在建立批准后Comp360服务提供商培训体系","url":"https://stock-news.laohu8.com/highlight/detail?id=1130056728","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1130056728?lang=zh_cn&edition=full","pubTime":"2026-04-14 18:32","pubTimestamp":1776162733,"startTime":"0","endTime":"0","summary":"COMPASS Pathways plc近日宣布启动一项美国资助计划,该计划致力于构建针对Comp360治疗方案获批后的专业医疗服务提供者培训体系。此举旨在通过系统化培训提升医疗人员对创新疗法的专业应用能力,为患者提供更规范的医疗服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148114808","title":"COMPASS Pathways公司:截至2024年3月现金状况预计足以支撑运营支出及资本支出至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=1148114808","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148114808?lang=zh_cn&edition=full","pubTime":"2026-03-24 19:37","pubTimestamp":1774352236,"startTime":"0","endTime":"0","summary":"根据最新披露,COMPASS Pathways plc(简称CMPS)在2024年3月底的现金储备状况表现强劲,足以覆盖公司日常运营支出及未来资本开支需求,资金可持续性预计将延续至2028年。这一稳健的财务基础为公司在精神健康治疗领域的创新药物研发提供了有力支撑,同时也增强了市场对其长期发展战略的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518775752","title":"Compass Pathways Plc盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518775752","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518775752?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:14","pubTimestamp":1741616041,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时14分,Compass Pathways Plc股票出现异动,股价大幅下挫5.04%。截至发稿,该股报3.55美元/股,成交量21.0456万股,换手率0.23%,振幅6.66%。Compass Pathways Plc股票所在的医疗设施行业中,整体涨幅为2.80%。Compass Pathways Plc公司简介:Compass Pathways PLC是一家精神保健公司,致力于加快患者获得精神健康领域的循证创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022140198a2a7d8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022140198a2a7d8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517162333","title":"Compass Pathways Plc2024财年实现净利润-1.55亿美元,同比减少30.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517162333","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517162333?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276864,"startTime":"0","endTime":"0","summary":"3月7日,Compass Pathways Plc公布财报,公告显示公司2024财年净利润为-1.55亿美元,同比减少30.25%;其中营业收入为0.00美元,每股基本收益为-2.30美元。从资产负债表来看,Compass Pathways Plc总负债58.97百万美元,其中短期债务7.24百万美元,资产负债比为0.04,流动比率为0.06。机构评级:截至2025年3月7日,当前有10家机构对Compass Pathways Plc目标价做出预测,其中目标均价为16.50美元,其中最低目标价为9.00美元,最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000120a262a609&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000120a262a609&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517929763","title":"Compass Pathways Plc盘中异动 快速拉升5.06%报4.05美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517929763","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517929763?lang=zh_cn&edition=full","pubTime":"2025-03-06 04:59","pubTimestamp":1741208394,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日04时59分,Compass Pathways Plc股票出现波动,股价大幅上涨5.06%。截至发稿,该股报4.05美元/股,成交量75.022万股,换手率0.81%,振幅5.97%。Compass Pathways Plc股票所在的医疗设施行业中,整体涨幅为2.10%。Compass Pathways Plc公司简介:Compass Pathways PLC是一家精神保健公司,致力于加快患者获得精神健康领域的循证创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045954abea1e02&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306045954abea1e02&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517834849","title":"Compass Pathways Plc盘中异动 下午盘急速上涨5.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517834849","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517834849?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:02","pubTimestamp":1741118557,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时02分,Compass Pathways Plc股票出现波动,股价大幅上涨5.09%。Compass Pathways Plc股票所在的医疗设施行业中,整体涨幅为0.66%。其相关个股中,Kindly Md Inc C/Wts 31/05/2029 、Agilon Health, Inc.、Compass Pathways Plc涨幅较大,Newgenivf Group Limited、阿卡迪亚医疗保健、Imac Holdings, Inc.较为活跃,换手率分别为46.44%、2.94%、1.93%,振幅较大的相关个股有Newgenivf Group Limited C/Wts 03/04/2029、P3 Health Partners Inc C/Wts 19/11/2026 、The Oncology Institute, Inc.,振幅分别为47.60%、33.33%、24.24%。Compass Pathways Plc公司简介:Compass Pathways PLC是一家精神保健公司,致力于加快患者获得精神健康领域的循证创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305040237989bf7fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305040237989bf7fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516465194","title":"Compass Pathways Plc盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516465194","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516465194?lang=zh_cn&edition=full","pubTime":"2025-03-04 01:43","pubTimestamp":1741023813,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日01时43分,Compass Pathways Plc股票出现波动,股价大幅下跌5.22%。截至发稿,该股报3.73美元/股,成交量38.7908万股,换手率0.42%,振幅9.16%。Compass Pathways Plc股票所在的医疗设施行业中,整体涨幅为0.95%。Compass Pathways Plc公司简介:Compass Pathways PLC是一家精神保健公司,致力于加快患者获得精神健康领域的循证创新。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304014333abe66cfa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304014333abe66cfa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514320403","title":"Compass Pathways Plc盘中异动 早盘股价大跌5.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514320403","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514320403?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:38","pubTimestamp":1740753524,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时38分,Compass Pathways Plc股票出现波动,股价快速下跌5.10%。Compass Pathways Plc股票所在的医疗设施行业中,整体跌幅为4.08%。Compass Pathways Plc公司简介:Compass Pathways PLC是一家精神保健公司,致力于加快患者获得精神健康领域的循证创新。消息层面,截至22时38分,《RBC:上半年有望迎来积极催化剂 COMPASS Pathways等12只中小型医药股值得一看》资讯为影响Compass Pathways Plc的重要信息。RBC予COMPASS Pathways“跑赢大盘”评级,目标价为15美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822384596341b4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822384596341b4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasspathways.com","stockEarnings":[{"period":"1week","weight":0.0814},{"period":"1month","weight":0.0091},{"period":"3month","weight":0.1879},{"period":"6month","weight":1.2457},{"period":"1year","weight":1.7385},{"period":"ytd","weight":1.0797}],"compareEarnings":[{"period":"1week","weight":-0.0077},{"period":"1month","weight":-0.0106},{"period":"3month","weight":0.0304},{"period":"6month","weight":0.154},{"period":"1year","weight":0.1622},{"period":"ytd","weight":0.1208}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"COMPASS Pathways plc最初于2020年6月根据英格兰和威尔士法律成立为一家私人有限公司。该公司是一家生物技术公司,致力于加速推动患者获得基于证据的精神健康创新疗法。该公司正在通过开发他们的研究性COMP360 psilocybin治疗,开创一种以快速和持久反应为重点的治疗心理健康状况的新范式,这可能是同类治疗中的首创。COMP360是他们专有的裸盖菇素制剂,其中包括他们的医药级多形结晶裸盖菇素,针对稳定性和纯度进行了优化。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.053854},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.067409},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.124725},{"month":4,"riseRate":0.5,"avgChangeRate":0.092687},{"month":5,"riseRate":0.5,"avgChangeRate":0.037097},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001204},{"month":7,"riseRate":0.666667,"avgChangeRate":0.185901},{"month":8,"riseRate":0.5,"avgChangeRate":0.026891},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.073954},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.009194},{"month":11,"riseRate":0.333333,"avgChangeRate":0.034765},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.01163}],"exchange":"NASDAQ","name":"COMPASS Pathways plc","nameEN":"COMPASS Pathways plc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COMPASS Pathways plc(CMPS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供COMPASS Pathways plc(CMPS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"COMPASS Pathways plc,CMPS,COMPASS Pathways plc股票,COMPASS Pathways plc股票老虎,COMPASS Pathways plc股票老虎国际,COMPASS Pathways plc行情,COMPASS Pathways plc股票行情,COMPASS Pathways plc股价,COMPASS Pathways plc股市,COMPASS Pathways plc股票价格,COMPASS Pathways plc股票交易,COMPASS Pathways plc股票购买,COMPASS Pathways plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COMPASS Pathways plc(CMPS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供COMPASS Pathways plc(CMPS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}